Bain Capital Life Sciences, Cormorant Asset Management and RA Capital co-led the Staidson-backed inflammatory disease drug developer's latest round.
InflaRx, a Germany-based inflammatory disease drug developer that counts pharmaceutical firm Staidson Biopharmaceuticals as an investor, announced a $55m series D round on Friday.
Bain Capital Life Sciences, a fund overseen by private equity firm Bain Capital, co-led the round with hedge fund sponsor Cormorant Asset Management and investment management firm RA Capital Management, while included unnamed investment funds also participated.
The round consisted of $30m in equity funding and $25m that was put into a secondary share purchase. It…
